KMPH
Income statement / Annual
Last year (2022), KemPharm, Inc.'s total revenue was $10.46 M,
a decrease of 63.50% from the previous year.
In 2022, KemPharm, Inc.'s net income was -$41.54 M.
See KemPharm, Inc.,s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
Operating Revenue |
$10.46 M |
$28.65 M |
$13.29 M |
$12.84 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
Cost of Revenue |
$343,000.00
|
$2.06 M
|
$1.31 M
|
$2.95 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit |
$10.12 M
|
$26.59 M
|
$11.98 M
|
$9.89 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Gross Profit Ratio |
0.97
|
0.93
|
0.9
|
0.77
|
0
|
0
|
0
|
0
|
0
|
0
|
Research and Development Expenses |
$19.61 M
|
$10.16 M
|
$8.84 M
|
$19.42 M
|
$41.76 M
|
$20.59 M
|
$20.47 M
|
$13.93 M
|
$11.92 M
|
$3.37 M
|
General & Administrative Expenses |
$15.34 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$17.01 M
|
$8.88 M
|
$0.00
|
$1.35 M
|
Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General & Administrative Expenses |
$15.34 M
|
$8.70 M
|
$7.92 M
|
$10.82 M
|
$12.51 M
|
$12.77 M
|
$17.01 M
|
$8.88 M
|
$0.00
|
$1.35 M
|
Other Expenses |
$17.66 M
|
$2.06 M
|
$2.13 M
|
$2.95 M
|
$1.64 M
|
$0.00
|
$3.01 M
|
$0.00
|
-$28.36 M
|
$0.00
|
Operating Expenses |
$34.96 M
|
$18.86 M
|
$16.76 M
|
$30.23 M
|
$54.27 M
|
$33.37 M
|
$37.48 M
|
$22.81 M
|
-$16.44 M
|
$4.72 M
|
Cost And Expenses |
$35.30 M
|
$20.92 M
|
$18.07 M
|
$33.18 M
|
$54.27 M
|
$33.37 M
|
$37.48 M
|
$22.81 M
|
$16.44 M
|
$4.72 M
|
Interest Income |
$760,000.00
|
$248,000.00
|
$89,000.00
|
$309,000.00
|
$420,000.00
|
$365,000.00
|
$353,000.00
|
$32,000.00
|
$4,283.00
|
$52,000.00
|
Interest Expense |
$335,000.00
|
$376,000.00
|
$7.09 M
|
$6.51 M
|
$7.09 M
|
$7.34 M
|
$7.13 M
|
$2.67 M
|
$2.72 M
|
$157,000.00
|
Depreciation & Amortization |
$760,000.00
|
$248,000.00
|
$89,000.00
|
$309,000.00
|
$324,000.00
|
$336,000.00
|
$175,000.00
|
$84,000.00
|
$74,763.00
|
$68,000.00
|
EBITDA |
-$24.08 M |
$7.98 M |
-$4.69 M |
-$20.03 M |
-$49.18 M |
-$35.76 M |
-$9.23 M |
-$51.88 M |
-$21.69 M |
-$5.02 M |
EBITDA Ratio |
-2.3
|
0.28
|
-0.35
|
-1.56
|
0
|
0
|
0
|
0
|
0
|
0
|
Operating Income Ratio |
-2.38
|
0.27
|
-0.36
|
-1.58
|
0
|
0
|
0
|
0
|
0
|
0
|
Total Other Income/Expenses Net |
-$17.49 M
|
-$16.25 M
|
-$7.19 M
|
-$4.21 M
|
-$689,000.00
|
-$10.06 M
|
$20.95 M
|
-$31.82 M
|
-$8.03 M
|
-$528,000.00
|
Income Before Tax |
-$42.33 M
|
-$8.52 M
|
-$12.79 M
|
-$24.54 M
|
-$56.59 M
|
-$43.43 M
|
-$16.53 M
|
-$54.64 M
|
-$24.48 M
|
-$5.25 M
|
Income Before Tax Ratio |
-4.05
|
-0.3
|
-0.96
|
-1.91
|
0
|
0
|
0
|
0
|
0
|
0
|
Income Tax Expense |
-$786,000.00
|
$34,000.00
|
-$34,000.00
|
-$22,000.00
|
-$126,000.00
|
-$43,000.00
|
-$15,000.00
|
$26,000.00
|
-$22,247.00
|
-$20,000.00
|
Net Income |
-$41.54 M
|
-$8.56 M
|
-$12.76 M
|
-$24.52 M
|
-$56.47 M
|
-$43.39 M
|
-$16.52 M
|
-$54.66 M
|
-$24.45 M
|
-$5.23 M
|
Net Income Ratio |
-3.97
|
-0.3
|
-0.96
|
-1.91
|
0
|
0
|
0
|
0
|
0
|
0
|
EPS |
-1.2 |
-0.29 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
-50.01 |
-10.69 |
EPS Diluted |
-1.2 |
-0.29 |
-3.21 |
-13.23 |
-50.39 |
-47.37 |
-18.1 |
-118.69 |
-50.01 |
-10.69 |
Weighted Average Shares Out |
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915,806.00
|
$912,315.00
|
$460,542.00
|
$488,959.00
|
$488,959.00
|
Weighted Average Shares Out Diluted |
$34.49 M
|
$29.77 M
|
$3.98 M
|
$1.85 M
|
$1.12 M
|
$915,806.00
|
$912,315.00
|
$460,542.00
|
$488,959.00
|
$488,959.00
|
Link |
|
|
|
|
|
|
|
|
|
|